The post analyses patent law updates relating to COVID-19, including India’s push for TRIPS flexibilities and scrutiny of Gilead’s Remdesvir patent. It also covers the EPO’s stance on plant and animal patentability and new global initiatives in IP law enforcement.
Read more about COVID crisis threatens Gilead’s patent on Remdesvir, EPO’s Enlarged Board of Appeal issues opinion on plant and animal patentability, India asks G20 to establish agreement enabling use of TRIPS flexibilities and other patent news